Myriad Genetics

Yahoo Finance • 27 days ago

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi, a telehealth solution for breast cancer... Full story

Yahoo Finance • 30 days ago

Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth

Highlights Fourth quarter 2024 revenue of $211 million, grew 7% year-over-year driven by continued demand for Pharmacogenomics (14%) and Prenatal (12%) testing.Fourth quarter GAAP gross margin of 71.7%, increased 300 basis points year-ove... Full story

Yahoo Finance • 30 days ago

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic a... Full story

Yahoo Finance • last month

Myriad Genetics Included in Forbes America’s Best Employers 2025 List

SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, has been named on the Forbes list of America’s Best Employers 2025. This presti... Full story

Yahoo Finance • last month

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

Myriad Genetics, Inc. Management will participate in three upcoming investor healthcare conferences SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and... Full story

Yahoo Finance • 2 months ago

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance... Full story

Yahoo Finance • 2 months ago

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and Trademark Office has issued two new... Full story

Yahoo Finance • 2 months ago

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreeme... Full story

Yahoo Finance • 2 months ago

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal M... Full story

Yahoo Finance • 2 months ago

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing comprehensive information about reproductive and... Full story

Yahoo Finance • 2 months ago

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used... Full story

Yahoo Finance • 6 months ago

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the us... Full story

Yahoo Finance • 6 months ago

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issu... Full story

Yahoo Finance • 7 months ago

Insider Sale at Myriad Genetics Inc (MYGN): SVP, Chief of Staff Margaret Ancona Sells Shares

On August 21, 2024, Margaret Ancona, Senior Vice President, Chief of Staff at Myriad Genetics Inc (NASDAQ:MYGN), executed a sale of 11,538 shares of the company. Following this transaction, the insider now owns 79,366 shares of Myriad Gene... Full story

Yahoo Finance • 7 months ago

Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Myriad Genetics, Inc. SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor... Full story

Yahoo Finance • 10 months ago

Insider Sale: Director Lee Newcomer Sells 6,200 Shares of Myriad Genetics Inc (MYGN)

On May 13, 2024, Director Lee Newcomer sold 6,200 shares of Myriad Genetics Inc (NASDAQ:MYGN) as reported in a recent SEC Filing. The transaction occurred at a price of $25.3 per share. Warning! GuruFocus has detected 4 Warning Signs with... Full story

Yahoo Finance • 12 months ago

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Myriad Genetics, Inc. Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic tes... Full story

Yahoo Finance • last year

Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents

SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its SneakPeek® Early Gend... Full story

Yahoo Finance • last year

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

SALT LAKE CITY and FREMONT, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc., a leader in advanced genomics for precision oncology, (... Full story

Yahoo Finance • last year

Myriad Genetics to Participate in Stephens Annual Investment Conference

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the Stephens Annual Investment Conference... Full story